Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/194390
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Brasó Maristany, Fara | - |
dc.contributor.author | Griguolo, Gaia | - |
dc.contributor.author | Chic, Núria | - |
dc.contributor.author | Pascual, Tomás | - |
dc.contributor.author | Paré Brunet, Laia | - |
dc.contributor.author | Maues, Julia | - |
dc.contributor.author | Galván, Patricia | - |
dc.contributor.author | Dieci, Maria Vittoria | - |
dc.contributor.author | Miglietta, Federica | - |
dc.contributor.author | Giarratano, Tommaso | - |
dc.contributor.author | Martínez Sáez, Olga | - |
dc.contributor.author | Marín Aguilera, Mercedes | - |
dc.contributor.author | Schettini, Francesco | - |
dc.contributor.author | Conte, Benedetta | - |
dc.contributor.author | Angelats, Laura | - |
dc.contributor.author | Vidal Losada, Maria Jesús | - |
dc.contributor.author | Adamo, Barbara | - |
dc.contributor.author | Muñoz, Montse | - |
dc.contributor.author | Sanfeliu, Esther | - |
dc.contributor.author | González Farré, Blanca | - |
dc.contributor.author | Vivancos, Ana | - |
dc.contributor.author | Villagrasa, Patricia | - |
dc.contributor.author | Parker, Joel S. | - |
dc.contributor.author | Perou, Charles M. | - |
dc.contributor.author | Conte, Pierfranco | - |
dc.contributor.author | Prat Aparicio, Aleix | - |
dc.contributor.author | Guarneri, Valentina | - |
dc.date.accessioned | 2023-03-01T14:10:05Z | - |
dc.date.available | 2023-12-31T06:10:21Z | - |
dc.date.issued | 2022-12 | - |
dc.identifier.issn | 0027-8874 | - |
dc.identifier.uri | http://hdl.handle.net/2445/194390 | - |
dc.description.abstract | In advanced HER2-positive (HER2+) breast cancer (BC), the new antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is more effective compared to trastuzumab emtansine (T-DM1). However, T-DXd can have significant toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if pre-established levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29% and 56%, respectively (P<.001). ERBB2 mRNA was significantly associated with better progression-free survival (p = 0.002) and overall survival (OS; P = 0.02). These findings were independent of HER2 IHC levels, hormone receptor, age, brain metastasis and line of therapy. The HER2DX risk-score (P=.04) and the immunoglobulin (IGG) signature (P=.04) were significantly associated with OS since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ BC. | - |
dc.format.extent | 14 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Oxford University Press | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1093/jnci/djac227 | - |
dc.relation.ispartof | JNCI: Journal of The National Cancer Institute, 2022 | - |
dc.relation.uri | https://doi.org/10.1093/jnci/djac227 | - |
dc.rights | (c) Brasó Maristany, Fara et al., 2022 | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Tumors cerebrals | - |
dc.subject.classification | Metàstasi | - |
dc.subject.classification | Càncer de mama | - |
dc.subject.classification | Expressió gènica | - |
dc.subject.classification | Cèl·lules T | - |
dc.subject.other | Brain tumors | - |
dc.subject.other | Metastasis | - |
dc.subject.other | Breast cancer | - |
dc.subject.other | Gene expression | - |
dc.subject.other | T cells | - |
dc.title | HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1 | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 731692 | - |
dc.date.updated | 2023-03-01T14:10:05Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 36576009 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
731692.pdf | 1.6 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.